Loading stock data…
PHR
$9.67+0.46 (+4.99%)
Market ClosedLast close May 1
Phreesia, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phreesia, Inc. in the Healthcare sector is trading at $9.67. The stock is currently near its 52-week low of $7.77, remaining 48.5% below its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why PHR maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.67
Potential Downside
92.2%
Whystock Fair Value$0.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Buy
Mean target$16.17+67.2%
Range$10.00 – $24.00
Fundamentals
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$566.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
233.00
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.68%
Volume
Today's trading volume
1.26M
Recent News
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX's rising cash flow, DAAP adoption and expanding pharma ties boost outlook despite near-term revenue softness and cautious client spending.
Do Options Traders Know Something About Phreesia Stock We Don't?
Investors need to pay close attention to PHR stock based on the movements in the options market lately.
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?
OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.
Wells Fargo Maintains Overweight Rating on Phreesia (PHR)
Phreesia, Inc. (NYSE:PHR) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 5, 2026, Wells Fargo lowered the price target on Phreesia, Inc. (NYSE:PHR) to $15 from $25 and maintained an Overweight rating. Wells Fargo said fiscal 2027 revenue guidance “decelerated sharply,” largely driven by the Network segment, citing valuation compression and […]
Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
Phreesia is well-positioned to capture growth and market share but faces headwinds as visibility dims and questions arise.